Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Commentary on:D. (2020). Aspirin and other non‐steroidal anti‐inflammatory drugs for the prevention of dementia. Cochrane Database of Systematic Reviews, (4).
Implications for practice and research
Further studies of nonsteroidal anti-inflammatory drugs need to give due attention to the safety concerns arising from these existing studies.
Monitoring the risks of bleeding when prescribing aspirin or non-steroidal medications for patients with dementia in clinical practice is important.
According to the Centers for Disease Control and Prevention, 5 million adults were diagnosed with dementia in 2014; projected to rise to approximately 14 million by 2060.1 This is a significant health problem, as dementia prevalence is increasing. Therefore, practitioners need to understand how it can be prevented and treated effectively. To date, no available medication exists to prevent or delay the onset of dementia. It has been reported that the pathogenesis of dementia was associated with inflammation; therefore, medications with anti‐inflammatory properties such as aspirin and Nonsteroidal anti-inflammatory drugs (NSAIDs) could …
Correction notice This article has been corrected since it appeared Online First. Author name Kasha has been updated to Kesha.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.